Evidence map›Paper›PMID 26399241›Full record

ArticleImmunogenetics2015

The common equine class I molecule Eqca-1*00101 (ELA-A3.1) is characterized by narrow peptide binding and T cell epitope repertoires.

Tobias Bergmann, Carrie Moore, John Sidney, Donald Miller, Rebecca Tallmadge, Rebecca M Harman, Carla Oseroff, Amanda Wriston, Jeffrey Shabanowitz, Donald F Hunt and 4 more

Open access · greenAbstract read
In one paragraph

Article in Immunogenetics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Tobias BergmannInstitut für Virologie, Freie Universtiät Berlin, 14163, Berlin, Germany.
Carrie MooreDepartment of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA, 92037, USA.
John SidneyDepartment of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA, 92037, USA.
Donald MillerBaker Institute for Animal Health, College of Veterinary Medicine, Cornell University, Ithaca, NY, 14853, USA.
Rebecca TallmadgeDepartment of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, 14853, USA.
Rebecca M HarmanBaker Institute for Animal Health, College of Veterinary Medicine, Cornell University, Ithaca, NY, 14853, USA.
Carla OseroffDepartment of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA, 92037, USA.
Amanda WristonDepartment of Chemistry, University of Virginia, Charlottesville, VA, 22904, USA.
Jeffrey ShabanowitzDepartment of Chemistry, University of Virginia, Charlottesville, VA, 22904, USA.
Donald F HuntDepartment of Chemistry, University of Virginia, Charlottesville, VA, 22904, USA.
Nikolaus OsterriederInstitut für Virologie, Freie Universtiät Berlin, 14163, Berlin, Germany.
Bjoern PetersDepartment of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA, 92037, USA.
Douglas F AntczakBaker Institute for Animal Health, College of Veterinary Medicine, Cornell University, Ithaca, NY, 14853, USA.
Alessandro SetteDepartment of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA, 92037, USA. alex@lji.org.
La Jolla Institute for Immunology · USCornell University · USUniversity of Virginia · USFreie Universität Berlin · DE

Funding

Systems Biological Analysis of Innate and Adaptive Responses to VaccinationU19AI090023 · NIAID · EMORY UNIVERSITY · PI AHMED, RAFI, LI, SHUZHAO · 2010 to 2021
$45.0M
PROCESSED ANTIGEN CHARACTERIZATION BY MASS SPECTROMETRYR37AI033993 · NIAID · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI HUNT, DONALD F · 1999 to 2008
$5.6M
PROCESSED ANTIGEN CHARACTERIZATION BY MASS SPECTROMETRYR01AI033993 · NIAID · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI HUNT, DONALD F · 1994 to 2017
$4.9M
A Rational Approach for HIV Vaccine T Cell Epitope SelectionR01AI112566 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI GOEPFERT, PAUL A. · 2014 to 2017
$1.9M
NIAID NIH HHS AI 033993NIAID NIH HHS HHSN272200900042CNIAID NIH HHS HHSN272201400045CNIAID NIH HHS R01 AI033993NIAID NIH HHS R01 AI112566NIAID NIH HHS R01AI112566NIAID NIH HHS R37 AI033993NIAID NIH HHS U19 AI090023NIAID NIH HHS U19AI090023PHS HHS HHSN272200900042CPHS HHS HHSN272201400045C
6 · The paper itself

Abstract

Here we describe a detailed quantitative peptide-binding motif for the common equine leukocyte antigen (ELA) class I allele Eqca-1*00101, present in roughly 25 % of Thoroughbred horses. We determined a preliminary binding motif by sequencing endogenously bound ligands. Subsequently, a positional scanning combinatorial library (PSCL) was used to further characterize binding specificity and derive a quantitative motif involving aspartic acid in position 2 and hydrophobic residues at the C-terminus. Using this motif, we selected and tested 9- and 10-mer peptides derived from the equine herpesvirus type 1 (EHV-1) proteome for their capacity to bind Eqca-1*00101. PSCL predictions were very efficient, with an receiver operating characteristic (ROC) curve performance of 0.877, and 87 peptides derived from 40 different EHV-1 proteins were identified with affinities of 500 nM or higher. Quantitative analysis revealed that Eqca-1*00101 has a narrow peptide-binding repertoire, in comparison to those of most human, non-human primate, and mouse class I alleles. Peripheral blood mononuclear cells from six EHV-1-infected, or vaccinated but uninfected, Eqca-1*00101-positive horses were used in IFN-γ enzyme-linked immunospot (ELISPOT) assays. When we screened the 87 Eqca-1*00101-binding peptides for T cell reactivity, only one Eqca-1*00101 epitope, derived from the intermediate-early protein ICP4, was identified. Thus, despite its common occurrence in several horse breeds, Eqca-1*00101 is associated with a narrow binding repertoire and a similarly narrow T cell response to an important equine viral pathogen. Intriguingly, these features are shared with other human and macaque major histocompatibility complex (MHC) molecules with a similar specificity for D in position 2 or 3 in their main anchor motif.

Indexed as

AllelesAnimalsEpitopes, T-LymphocyteHerpesviridae InfectionsHerpesvirus 1, EquidHistocompatibility Antigens Class IHorse DiseasesHorsesHumansLeukocytes, MononuclearMicePeptide FragmentsProtein BindingProteomeTandem Mass SpectrometryT-Lymphocytes, CytotoxicEpitopes, T-LymphocyteHistocompatibility Antigens Class IPeptide FragmentsProteomeEquus caballus (Eqca)MHC binding motifMHC class IPeptide bindingT cell epitope

Identifiers

PMID26399241
PMCPMC4783141
OpenAlexW2124665270

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.